S-1: Turn Therapeutics Faces Going Concern Amid Drug Development Push

Turn Therapeutics, a biopharmaceutical company, reported significant losses and expressed substantial doubt about its ability to continue as a going concern, despite advancing multiple drug and medical device candidates.

Summary

• Turn Therapeutics is a clinical-stage biopharmaceutical company focused on dermatology (eczema, onychomycosis) and vaccine development, leveraging its proprietary PermaFusion platform.
• The PermaFusion platform enables stable suspension of water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without emulsifiers, improving bioavailability and reducing API load.
• The company has three FDA-cleared medical devices (Hexagen for wounds, AtopX for dermatitis, XEAL antimicrobial gauze) but is not currently generating revenue from them, focusing instead on drug development.
• GX-03/Hexagen is being developed as a drug candidate for moderate-to-severe eczema and onychomycosis, with human trials for eczema initiated in mid-July 2025 (Phase 2-equivalent).
• The FDA has indicated that existing 510(k) clinical data may allow the company to bypass Phase 2 studies and proceed directly to pivotal Phase 3 trials for eczema and onychomycosis.
• A collaboration with an international non-profit is advancing a thermostable, intranasal Marburg virus vaccine, with successful 100% recovery of a live VSV-based vaccine vector after 14 days ambient storage and 28 days refrigerated storage.
• Preclinical in-vivo studies for herpes zoster ophthalmicus (shingles of the eye) showed an 85% reduction in viral load, and for basal cell carcinoma, Hexagen showed a 29% reduction in tumor size compared to placebo and 20% compared to 5-Fluorouracil.
• The company reported net losses of $1.57 million for the six months ended June 30, 2025, and $1.77 million for the year ended December 31, 2024.
• An accumulated deficit of $20.76 million was reported as of June 30, 2025, and $19.20 million as of December 31, 2024.
• Cash and cash equivalents were $3.19 million as of June 30, 2025, and $0.9 million as of December 31, 2024.
• Management believes existing capital will fund operations into the fourth quarter of 2025, but substantial additional funding (estimated $18.0-$20.0 million for Phase 3 trials, $1.5-$2.5 million for vaccine program) is required.
• A material weakness in internal control over financial reporting related to stock-based compensation accounting was identified.
• The company entered into a Share Purchase Agreement with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited (GEM) for up to $85.0 million in equity financing, subject to drawdown notices and conditions.
• A warrant to purchase 1,192,207 shares at an exercise price of $5.03 per share was issued to GEM on October 8, 2025, along with a 1% commitment fee (50,801 shares at an assumed $16.73 Reference Price).
• The founder, Bradley Burnam, controls approximately 52% of outstanding common stock on a fully diluted basis, making the company a 'controlled company' under Nasdaq rules.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including substantial losses and a 'going concern' warning, indicating high operational risk. While there are promising preclinical and early-stage clinical results for its product pipeline and a committed equity financing facility, the immediate financial instability and the long, uncertain path to drug approval weigh heavily on the sentiment. The dilution risk from the GEM agreement and the founder's control are also notable concerns.

Positives

• Proprietary PermaFusion platform enables stable suspension of APIs in oil-based carriers, enhancing bioavailability and reducing API load.
• Platform validated across multiple FDA-cleared medical devices (Hexagen, AtopX, XEAL).
• Drug candidates for moderate-to-severe eczema and onychomycosis are in development, with human trials for eczema initiated.
• FDA has indicated potential to bypass Phase 2 studies for eczema and onychomycosis, accelerating development.
• Successful 100% recovery of live VSV-based vaccine vector in thermostability studies for Marburg virus vaccine candidate (up to 14 days ambient, 28 days refrigerated).
• Preclinical studies show promising results: 85% viral load reduction in herpes zoster ophthalmicus and 20-29% tumor size reduction in basal cell carcinoma.
• GX-03/Hexagen demonstrated significant inhibition of key eczema-related cytokines (IL-36, IL-31, IL-4) in animal models.
• Established real-world tolerability record with over 200,000 applications of platform products without reported adverse events.
• Strong intellectual property portfolio with 13 issued U.S. patents and multiple pending applications, providing coverage into the 2040s.
• Capital-efficient operating model leverages contractors and vendors to minimize cash burn and focus on clinical development.
• Positioned to capitalize on market disruption and patent expirations of incumbent dermatology and antifungal therapies.
• MiMedx agreement provides potential milestone payments up to $69.55 million for FleX Product and mid-single digit royalties on net sales.

Negatives

• Incurred significant net losses: $1.57 million for six months ended June 30, 2025, and $1.77 million for year ended December 31, 2024.
• Accumulated deficit of $20.76 million as of June 30, 2025.
• Consolidated financial statements express substantial doubt about the ability to continue as a going concern due to insufficient capital.
• Limited operating history and unproven revenue/income potential for drug development.
• Reliance on third parties for manufacturing and clinical trials introduces risks of delays, non-compliance, and increased costs.
• Intense competition from large, well-established pharmaceutical and medical device companies with greater resources.
• Identified a material weakness in internal control over financial reporting related to stock-based compensation accounting.
• Founder, Bradley Burnam, controls approximately 52% of voting power, potentially leading to interests differing from other shareholders.
• The GEM Purchase Agreement involves substantial dilution risk to existing shareholders, and the actual proceeds are unpredictable.
• No current revenue generation from medical devices as focus is on drug development, and no revenue-sharing agreement for a commercialized product in the prior two fiscal years.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring losses and insufficient capital to fund drug development plans.
• Inherent uncertainties and risks in pharmaceutical and medical device product development and commercialization, with no guarantee of profitability.
• Failure to obtain or generate necessary capital could lead to delays, reductions, or termination of product development programs.
• Financing agreements, such as the GEM Purchase Agreement, may lead to increased dilution and adversely impact stock price.
• Competition from large, well-established companies and innovative new companies could hinder market acceptance and growth.
• Material weakness in internal control over financial reporting may result in material misstatements of financial statements.
• Difficulties in managing anticipated organizational growth, including attracting and retaining talent.
• Reliance on third parties for manufacturing and clinical testing exposes the company to risks of non-compliance, supply shortages, and quality issues.
• Business is dependent on successful development, regulatory approval, and commercialization of products, which is lengthy, expensive, and uncertain.
• Clinical trials and preclinical studies are expensive, time-consuming, difficult to design, and involve uncertain outcomes, with potential for delays or failures.
• Failure to comply with government regulations (e.g., FDA, healthcare fraud and abuse laws) could result in substantial enforcement actions and penalties.
• Product liability suits due to defective design, material, workmanship, or misuse could lead to costly litigation and substantial damages.
• Product recalls could harm reputation and have a material adverse effect on business and financial results.
• Inability to obtain, maintain, and enforce patent protection, or challenges to existing patents (e.g., Marc Selner derivation proceeding), could harm competitive position.
• Failure to protect the confidentiality of trade secrets could harm business and competitive position.
• Cybersecurity breaches, attacks, or disruptions to information technology systems could compromise confidential information and expose the company to liability.
• An active trading market for common stock may not develop or remain liquid, leading to price volatility and difficulty selling shares.
• Sales of substantial amounts of common stock by founder, affiliates, or non-affiliates could reduce stock price.
• As a controlled company, the company may rely on exemptions from Nasdaq corporate governance rules, potentially reducing shareholder protections.
• Founder's significant ownership (52%) gives him substantial control, and his interests may differ from other shareholders.
• Inability to maintain Nasdaq listing could impair access to capital (e.g., GEM Purchase Agreement) and reduce stock value.
• Broad discretion over the use of proceeds from the GEM Purchase Agreement may not yield significant returns or align with investor preferences.
• Changes in U.S. patent law could diminish the value of patents, impairing protection of products.

Future Outlook

The company expects to incur substantial losses for the foreseeable future due to increased research and development costs for later-stage clinical trials. It anticipates needing significant additional funding to support ongoing drug development and operations, potentially through equity and debt financing or strategic collaborations. The plan is to advance to Phase 3 trials for moderate-to-severe eczema and onychomycosis following the current Phase 2-equivalent eczema trial and IND submission. For the Marburg vaccine, the company intends to pursue preclinical immunogenicity studies in animals before the end of 2025, followed by GLP toxicology and non-human primate challenge studies, and then Phase 1 and Phase 2 clinical trials in healthy adult volunteers. The company aims to establish a viable regulatory pathway for its new vaccine technology and believes the Marburg vaccine candidate may qualify for FDA expedited programs and a Priority Review Voucher. The company also intends to deepen its network of strategic partners and expand technology platform indications.

Management Comments

• "We believe this initiative highlights our platforms versatility and its potential to unlock new therapeutic categories beyond dermatology."
• "We believe these preclinical in-vivo studies suggest meaningful potential in these indications, which we may continue to explore at the conclusion of our lead drug programs."
• "We believe such exploratory results further underscore the potential breadth of opportunity enabled by our platform."
• "Our current business model is to license and/or sell medical device products through commercial partners which allows us to focus our internal efforts on drug development."
• "We maintain a business model that strategically leverages contractors and vendors while employing a comparatively small internal team in order to minimize cash burn rate."
• "We believe this reduces the amount of cash needed for internal operations, reduces waste and results in a larger proportion of available capital that can be spent toward furthering clinical development."
• "We believe such signals, along with PHMBs well-documented antimicrobial and anti-inflammatory properties, which have been validated by scientific literature and in-vivo studies, form a sound scientific basis for cross-indication effectiveness across these two dermatologic conditions."
• "We believe this favorable track record in real-world uses supports higher likelihoods of success for future regulatory submissions and provides a strong foundation for physician and patient confidence as we advance our therapeutic programs."
• "We believe this hybrid model of licensing and internal drug development positions us to grow while minimizing capital risk."
• "Our ability to generate non-dilutive cash flow from commercial device agreements is designed to support our pharmaceutical programs and extend our operational runway."
• "At the same time, successful advancement of one or more drug candidates could unlock significant long-term value through regulatory milestones, product approvals, and eventual market entry."
• "Looking ahead, we intend to deepen our network of strategic partners, expand the indications addressed by our technology platform, and pursue regulatory milestones that support broader commercialization opportunities both in the U.S. and internationally."
• "The company intends to retain rights to Hexagen-specific indications that intend for use of the product in its primary physical form (topical ointment form), including prescription and over the counter."
• "We believe these data support rapid skin-calming and anti-inflammatory effects of GX-03 and may provide early validation for its use in inflammatory skin conditions such as eczema."
• "We believe this suggests that the more convenient nature of a thermostable, intranasal vaccine could result in significant growth in vaccine uptake."
• "We believe this procurement history provides a relevant benchmark for the potential commercial pathway of our investigational intranasal Marburg virus vaccine."
• "We believe this will help address key tolerability concerns as compared to current therapies."

Industry Context

The company operates in the highly competitive biopharmaceutical and medical device industries, targeting large markets such as advanced wound care ($18.72 billion in 2024, projected to $30.76 billion by 2034), atopic dermatitis ($12.0-$18.0 billion), and onychomycosis ($3.81 billion in 2024). These markets have significant unmet needs, particularly for non-steroidal, non-systemic topical therapies in dermatology and thermostable, needle-free vaccines. The vaccine market is expanding, especially for global health threats, with potential for government procurement contracts (e.g., anthrax vaccine contracts exceeding $2 billion). The company's focus on platform technology and capital-efficient model aims to disrupt these markets, especially as patents for incumbent therapies expire.

Comparison to Industry Standards

• **Onychomycosis:** Current topical therapies like Jublia (efinaconazole) have low complete cure rates (often below 20%) and limited nail penetration. Oral antifungals offer better efficacy but carry systemic risks (e.g., hepatotoxicity, liver monitoring). Our topical GX-03/Hexagen is designed to overcome these limitations by enhancing nail plate penetration and avoiding systemic exposure, with independent studies suggesting clinical clearance rates as high as 70-85% in diverse patient populations.
• **Eczema/Atopic Dermatitis:** Current treatments include topical corticosteroids (limited by long-term side effects), calcineurin inhibitors, systemic immunosuppressants, and biologics like Dupixent (dupilumab). Dupixent, while effective, is an injectable biologic with high costs and systemic immunosuppression. Newer biological topicals like JAK inhibitors (e.g., Vtama) are hindered by high cost and poor safety profiles. Our GX-03/Hexagen is a non-steroidal, non-biologic topical immunotherapy with dual antimicrobial and anti-inflammatory mechanisms, demonstrating cytokine modulation without systemic absorption, addressing key tolerability concerns.
• **Vaccine Delivery (Marburg Virus):** Current vaccine candidates for Marburg virus require deep-frozen storage. Our intranasal formulation aims for thermostability, enabling distribution without deep-freeze, similar to the need for anthrax vaccine (BioThrax) stockpiling by the U.S. government (Emergent BioSolutions received over $2 billion in contracts). Our needle-free, thermostable approach offers operational advantages over injectable vaccines, particularly for military and emergency response, and may qualify for FDA's Animal Rule pathway, similar to Merck's Ervebo (Ebola Zaire virus vaccine).

Management Changes

Corporate Governance

Legal Proceedings

• The company was involved in a derivation proceeding in 2017 before the U.S. Patent and Trademark Office (USPTO) against Marc Selner, alleging improper filing of a patent application for an invention conceived by Bradley Burnam. The USPTO and the U.S. Court of Appeals for the Federal Circuit affirmed the USPTO's decision, resulting in Selner retaining the patent application.
• Should Selner's patent application ultimately issue as a patent, he may attempt to seek royalties or prevent the development and commercialization of Hexagen and products containing Hexagen, or otherwise seek damages from the company. The company would vigorously defend its rights, but there is no assurance of success.

Related Party Transactions

• **Employment Agreement with Bradley Burnam:** A new employment agreement became effective in connection with the direct listing, superseding the 2017 agreement. It sets a base salary of $575,000, a target annual cash bonus of 50% of base salary, and eligibility for annual equity incentive awards with a target grant date fair value of 50% of base salary. It also includes severance provisions for termination without cause or resignation for good reason, with enhanced benefits in case of a change of control.
• **Voting Proxy (Terminated):** In connection with a Regulation A offering, certain investors granted a voting proxy to the CEO, Bradley Burnam, which limited their voting ability. This proxy terminated in connection with the direct listing.
• **Indemnification Agreements:** The company has entered into indemnification agreements with each of its directors and executive officers, providing for indemnification to the fullest extent permitted by Delaware law.
• **Registration Rights Agreement with Bradley Burnam:** The company entered into an agreement with Bradley Burnam, granting him rights to request registration of his shares on a long-form or short-form registration statement and to participate in certain registered offerings.
• **Stockholders Agreement with Bradley Burnam:** An agreement with Bradley Burnam and his affiliated entity, BEB Holdings LLC, grants Mr. Burnam certain consent rights over corporate affairs as long as he beneficially owns at least 10% of the outstanding common stock. These rights include approval over mergers, asset sales, equity issuances exceeding $50 million, amendments to organizational documents, significant indebtedness, and senior management hiring/compensation decisions.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from the GEM Purchase Agreement and potential future capital raises. The 'going concern' warning indicates a high risk of investment loss. The founder's substantial control (52% voting power) and consent rights may limit the influence of other shareholders on major corporate decisions. The volatility of the stock price on Nasdaq is also a concern.
• **Employees:** The company expects to increase its organizational size, requiring additional managerial, operational, sales, marketing, and financial personnel, which could create new opportunities. However, the company's financial instability and reliance on contractors could pose job security risks.
• **Customers/Patients:** Potential for new, differentiated therapies for eczema, onychomycosis, and Marburg virus, addressing unmet needs and offering improved tolerability and delivery methods. However, the long and uncertain drug development process means these benefits are not immediate.
• **Suppliers/Creditors:** The 'going concern' warning and reliance on third-party manufacturers and CROs introduce risks regarding the company's ability to meet financial obligations. Concentration of accounts payable with two vendors (34% as of June 30, 2025) could pose risks if the company faces liquidity issues.
• **Regulatory Bodies:** The company is subject to extensive FDA and other regulatory oversight. Non-compliance could lead to sanctions, recalls, or delays, impacting product availability and public health.

Next Steps

• File an Investigational New Drug (IND) program to open Phase 3 studies for moderate-to-severe eczema and onychomycosis, leveraging data from the ongoing Phase 2-equivalent eczema trial.
• Conduct additional nonclinical and clinical studies, such as PK max-use and healthy volunteer exposure trials, potentially in parallel with Phase 3 trials.
• Attempt an animal model of the intranasal Marburg candidate to achieve an antibody response.
• Start an additional stability test of the Marburg candidate, extending ambient and 4C arms to 90 days.
• Pursue remaining preclinical, clinical, and regulatory steps with the international non-profit partner to bring the stabilized intranasal Marburg vaccine to market.
• Conduct a preclinical immunogenicity study of the intranasal Marburg vaccine candidate in a live animal model before the end of 2025.
• Conduct GLP toxicology studies and non-human primate challenge studies for the Marburg vaccine candidate.
• Initiate Phase 1 and Phase 2 clinical trials for the Marburg vaccine candidate in healthy adult volunteers (approximately 300-500 subjects) to evaluate safety, tolerability, and immunogenicity.
• Submit a Biologics License Application (BLA) to the FDA for the Marburg vaccine, if successful, supported by clinical, nonclinical efficacy, and CMC data.
• Actively identify potential partners for distribution of AtopX outside the United States.
• Secure an exclusive partner to market XEAL in the United States and globally.
• Implement a remediation plan for the identified material weakness in internal controls over financial reporting, including hiring personnel or engaging experts with GAAP expertise.
• Continue to raise substantial additional capital through public or private equity offerings, debt financings, or collaboration agreements to fund operations and development plans.

Key Dates

Recommendation

The company's financial statements explicitly state "substantial doubt about our ability to continue as a going concern," which is a critical red flag for investors. Despite promising preclinical and early-stage clinical data for its product pipeline and a committed equity financing facility, the company has a history of significant net losses and a growing accumulated deficit. The reliance on future, highly dilutive equity financing (GEM Purchase Agreement) and the unpredictable nature of drug development and regulatory approvals mean that the path to profitability is extremely uncertain and fraught with risk. The founder's controlling ownership and the identified material weakness in internal controls further add to governance and operational concerns. For a seasoned investor, the immediate financial instability and the high probability of further dilution make this a 'strong sell' recommendation, as the risks far outweigh the speculative potential for future success.

Keywords

Biopharmaceutical, Dermatology, Eczema, Onychomycosis, Vaccine Development, PermaFusion, Hexagen, PHMB, FDA Clearance, Clinical Trials, Going Concern, Equity Financing, Intellectual Property, Medical Device, Nasdaq Listing, Marburg Virus, Thermostable Vaccine, Atopic Dermatitis, Fungal Nail Infection